Q-omics provides the consensus-scored NDUFB4P2 profile across patient tissues and cancer cell-line models. NDUFB4P2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NDUFB4P2 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, NDUFB4P2 RNA expression shows 8,104 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UCS, BRCA, and LUAD as cancer lineages where NDUFB4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB4P2 survival associations across molecular data types. NDUFB4P2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB4P2 RNA expression–survival associations across cancer types. High NDUFB4P2 expression shows unfavorable associations in UCS, ESCA and THCA, but favorable associations in COAD, HNSC and ACC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UCS as the clearest survival context for NDUFB4P2 RNA expression.
This table summarizes NDUFB4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFB4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB4P2 shows higher tumor expression in BRCA, COAD and KIRC. The BRCA box plot shows higher NDUFB4P2 RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p = .026).
This table shows molecular features associated with NDUFB4P2 in patient tissues and cancer cell lines. In patient samples, NDUFB4P2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
